How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly

prevalence of thyroid nodules, no convincing data indicate an increased risk of thyroid cancer in patients with acromegaly above that expected in the general popula- tion with thyroid nodules (29 [EL 4]). Therefore, thyroid nodules in patients with acromegaly should be monitored according to standard guidelines. Most patients have nor- mal thyroid function, although the presence of hyperthy- roidism ranges from 4% to 14% (30 [EL 3]). In a patient with elevated serum thyroxine levels, the presence (...) . As a result, preoperative SSA therapy might be expected to result in reduction of intubation-related complications (Grade D). This issue, however, warrants further direct examination for higher quality of evidence. Patients with acromegaly are also at risk of cardiac complications, including left ventricular hypertrophy, increased stroke volume and cardiac index, biventricu- lar concentric cardiomyopathy, and, in advanced cases, reduced ejection fraction or cardiac failure. Up to 10% of patients

2011 American Association of Clinical Endocrinologists

182. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism (PubMed)

 < 0.05). Nonlinear regression and multivariable linear regression models all showed significant associations of resistin or adiponectin with free thyroxine and association of leptin with thyroid-stimulating hormone (p < 0.001). Furthermore, significant correlation between resistin and HOMA-IR was observed in the patients (p < 0.001). Thus, thyroid dysfunction affects the profile of lipids and adipokines. Resistin may serve as a link between thyroid dysfunction and insulin resistance. (...) and 355 control subjects. Hypothyroid patients presented with significantly higher serum levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDLC), fasting insulin, resistin and leptin than control (p < 0.05). Hyperthyroid patients presented with significantly lower serum levels of high-density lipoprotein cholesterol, LDLC and leptin, as well as higher levels of fasting insulin, resistin, adiponectin and homeostasis model insulin resistance index (HOMA-IR) than control (p

Full Text available with Trip Pro

2016 Scientific reports

183. Higher central fat and poor self-body image in short-stature overweight/obese women living in Brazilian shantytowns (PubMed)

for SS and mean: 0.60; standard deviation: 0.07 for the NS group; p = 0.02), and, in the adjusted analysis, showed lower fat-free mass (Estimated Marginal Mean for the SS group: 45.7 kg 95% confidence intervals (CI) (45.2-46.2) and for the NS group: 46.9 kg 95% CI (46.4-47.4); p < 0.01) and higher fat mass (Estimated Marginal Mean for the SS group: 32.5 95% CI (31.9-33.0) and for the NS group: 31.4 kg 95% CI (30.9-31.9); p < 0.01). Body mass index was a better predictor of current self-body-image (...) -sectional study was conducted with women living in shantytowns and mother or relatives to undernourished children treated in a center for recuperation and nutritional education. Inclusion criteria were: (1) age, 19-45 years; (2) stature < 152.3 cm or > 158.7 cm; and (3) body mass index > 25 kg/m2. Socioeconomic, anthropometric, biochemical, and body image data were collected. We analyzed 56 SS and 57 NS women.The SS group showed a higher waist-to-height ratio (WHtR) (mean: 0.63; standard deviation: 0.06

Full Text available with Trip Pro

2016 PeerJ

184. Postprandial Effects of High-fat Meals With Different Dairy Products on Lipid Metabolism and Inflammation

-density lipoprotein and high-density lipoprotein Changes in levels of apolipoproteins [ Time Frame: Measured at baseline and 2,4 and 6 hours after intake of test meal ] Changes in levels of apolipoproteins, i.e. apo A1, apo B, apo B-48 and apo C-III Changes in levels of free fatty acids [ Time Frame: Measured at baseline and 2,4 and 6 hours after intake of test meal ] Changes in levels of circulating inflammatory markers [ Time Frame: Measured at baseline and 2,4 and 6 hours after intake of test meal (...) Criteria Inclusion Criteria: The study will include both men and women aged 18-70 years with the aim of an even age and gender balance. Participants in the healthy group will need to have a body mass index (BMI) between 18.5 - 24.9 kg/m2 and a waist circumference (WC) of <94 cm for men and<80 cm for women. Participants in the obese group will need to have a BMI of ≥25 kg/m2 and a waist circumference of ≥94 cm for men and ≥80 cm for women. All subjects must be willing to eat three slices of bread

2016 Clinical Trials

185. Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

. Secondary objectives include response rates, local control, progression-free survival (PFS) and overall survival (OS). Exploratory endpoints include immunologic responses and response rates in PD-L1- TIL- tumors. The combination sequence with the most promising response rates and the best safety profile will be selected to continue in a Phase II trial. Condition or disease Intervention/treatment Phase Metastatic Urothelial Cancer Drug: pembrolizumab Phase 1 Study Design Go to Layout table for study (...) systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Has known history of, or any evidence of active, non-infectious pneumonitis. Has an active infection requiring systemic therapy. Has a history or current evidence of any condition, therapy

2016 Clinical Trials

186. Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

stimulating hormone (TSH) outside of the normal limits and clinically significant as determined by the investigator. Free thyroxine (T4) levels may be measured if TSH level is high. Subject will be excluded if T4 level is clinically significant. Any other clinically significant abnormal laboratory result at the time of the screening exam. 20. History of hypothyroidism and has been on a stable dosage of thyroid replacement medication for less than six months prior to screening.(Subjects on a stable dosage (...) which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline. Body mass index between 18-35kg/m2. Concurrent psychotherapy will be allowed if the type (e.g., supportive, cognitive behavioral, insight-oriented, et al) and frequency (e.g., weekly or monthly

2016 Clinical Trials

187. A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

Lung Cancer Drug: Pembrolizumab Radiation: Single Fraction Radiation Therapy Phase 2 Detailed Description: This is a Phase 2 randomized two arm phase II trial of pembrolizumab alone or sequentially following focal radiation to one of the target lesions, in previously treated patients with stage IV Non-Small Cell Lung Cancer (NSCLC). The primary goal of this trial is to compare the efficacy of focal radiation (RT) to an index lesion as a way of enhancing the anti-tumor immune response (...) in metastatic NSCLC. Secondary Objectives: To determine the progression-free and overall survival in patients with NSCLC receiving pembrolizumab, who receive Single Fraction Radiation Therapy (SFRT) To determine the safety and toxicity of the combination of SFRT and pembrolizumab To examine potential predictive biomarkers in tumor samples and peripheral blood in patients treated with pembrolizumab and SFRT To determine the local control of SFRT in the radiated lesion, when SFRT is given with pembrolizumab

2016 Clinical Trials

188. Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

of six clinical cohorts of high risk and recurrent disease. In addition to assessing the incidence and severity of adverse events and rates of complete response and progression free survival, investigators intend to monitor immune reconstitution, phenotype and TCR repertoire throughout treatment and at the time of disease progression. Investigators will also analyze the gut microbiome prior to conditioning, throughout treatment, post-transplant and at time of relapse. Condition or disease (...) and for complete response and progression free survival (PFS) rates. Complete response and progression free survival rates will be compared to published standards for each disease group. Expected PFS at 18 months for all post-transplant groups without check point inhibitors is less than 50%. Each group with PFS at 18 months in 4 or more patients (57%) will be considered for eligibility in a successor phase IIB expansion trial. Study Design Go to Layout table for study information Study Type : Interventional

2016 Clinical Trials

189. Renoprotective Effects of Dapagliflozin in Type 2 Diabetes

bladder scan) Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN (Unstable) thyroid disease; defined as free thyroxine (fT4) outside of laboratory reference values or change in treatment within 3 months prior to screening visit History of or actual malignancy (except basal cell carcinoma) History of or actual severe mental disease Substance abuse (alcohol (...) albumin excretion, neutrophil gelatinase-associated lipocalin and kidney injury molecule-1; blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®); body anthropometrics, including body weight, height, body-mass index and waist circumference, and body fat contents (by bio-impedance analysis) will be measured; blood samples will be obtained to determine glycemic variables, lipids and markers of inflammation; systemic hemodynamic variables (including stroke

2016 Clinical Trials

190. Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

administration. If needed (i.e. an incidental and limited need) ibuprofen is acceptable as analgesic treatment, but must be documented in the (Case Report Form) CRF. Use of paracetamol is forbidden during the entire study Subjects who are not in euthyroid condition (thyroid-stimulating hormone [TSH] and free thyroxine [fT4] within the normal reference range) Any history of suspected malignancy with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within (...) at screening and Day -1 30 to 65 years of age inclusive Body mass index between ≥18.0 and ≤30.0 kg/m2 Must be willing and able to communicate and participate in the whole study Must provide written informed consent Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)Must agree to use an adequate method of contraception Exclusion Criteria: Participation in a clinical research study within the previous 3 months Subjects who are study site employees, or immediate

2016 Clinical Trials

191. Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

and specific gravity. Part 1: Change from Baseline in Troponin I or Troponin T [ Time Frame: Baseline and up to 24 months ] Troponin I or Troponin T will be assessed by echocardiogram or multigated acquisition scans (MUGA). Part 1: Change from Baseline in thyroid stimulating hormone (TSH) [ Time Frame: Baseline and up to 24 months ] Blood samples will be collected at indicated time points and change from Baseline in TSH will be analyzed. Part 1: Change from Baseline in triiodothyronine (T3) and thyroxine (...) ) at any time, plus stable disease (SD) >=18 weeks. Part 1: Overall survival (OS) [ Time Frame: up to 4 years ] OS is defined as time from the date of first dose of study treatment to the date of death due to any cause. Part 1: Progression-free survival (PFS) [ Time Frame: Up to 27 months ] PFS is defined as time from the date of first dose of study treatment to the date of disease progression according to clinical or radiographic assessment or death due to any cause, whichever occurs earliest. Part 1

2016 Clinical Trials

192. Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

for TNBC. Patients having received any prior line of systemic therapy for inoperable/recurrent or metastatic disease are eligible. At least one tumor for which palliative RT is considered appropriate standard therapy. At least one index lesion that will not undergo RT and which is measurable based on RECIST 1.1. If an archived tumor tissue is available, be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up (...) dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. Note: ^aCreatinine clearance should be calculated per institutional standard. Exclusion Criteria: Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. Has a diagnosis

2016 Clinical Trials

193. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Between 18 and 70 years of age inclusive, at the time of signing the informed consent. Subject values for the following parameters thyroid-stimulating hormone (TSH), free thyroxine (T4 (...) ), and free triiodothyronine (T3) within the normal range. Subject has confirmed diagnosis of Lupus Erythematosus Tumidus (LET) (group A only), subacute or chronic CLE as determined by the investigators. Body weight >= 50 kg and body mass index (BMI) within the range 19.9 - 35 kilogram (kg)/meter square (m^2) (inclusive) Male OR Female. Females: Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion

2016 Clinical Trials

194. Saxenda in Obesity Services (STRIVE Study)

loss for another 52 weeks patient compliance [ Time Frame: 16, 32, 52 and 104 weeks ] referral rates to other obesity interventions [ Time Frame: 52 and 104 weeks ] Other Outcome Measures: Liver function tests [ Time Frame: Screening, 32, 52 and 104 weeks ] Biochemistry: Alkaline Transaminase (i u/L), Alkaline Phosphatase (i u/L), Total Bilirubin (umol/L), Albumin (g/L) Thyroid function tests [ Time Frame: Screening, 32, 52 and 104 weeks ] Biochemistry: Thyroid Stimulating Hormone (miu/L), Free (...) Thyroxine (pmol/L) Renal function tests [ Time Frame: Screening, 32, 52 and 104 weeks ] Biochemistry: Urea (mmol/L), Creatinine (umol/L), eGFR (mL/min) Haematology profile [ Time Frame: Screening, 32, 52 and 104 weeks ] Biochemistry: White Blood Cell Count (x10^9/L), Red blood cell count (x10^12/L), Haemoglobin (g/L), Haematocrit (L/L), Mean Cell Volume (fL), Mean Cell Haemoglobin (pg), Platelet Count (x10^9/L) Lipids [ Time Frame: Screening, 32, 52 and 104 weeks ] Biochemistry: Cholesterol (mmol/L

2016 Clinical Trials

195. Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects

of Free Triiodothyronine and Free Thyroxine at Baseline and Week 4 [ Time Frame: Baseline and Week 4 ] Blood samples were collected for measurement of Free Triiodothyronine (FT3) and Free Thyroxine (FT4) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') Absolute Values of Thyroid Stimulating Hormone at Baseline and Week 4 [ Time Frame: Baseline and Week 4 ] Blood samples were collected (...) Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: GlaxoSmithKline ClinicalTrials.gov Identifier: Other Study ID Numbers: 201614 First Posted: March 11, 2016 Results First Posted: April 6, 2017 Last Update Posted: April 6, 2017 Last Verified: January 2017 Keywords provided by GlaxoSmithKline: Pulmonary Arterial Hypertension (PAH) safety FLOLAN New Thermostable Formulation dose

2016 Clinical Trials

196. No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life and cognitive functioning in a large population-based cohort study. (PubMed)

because of primary hypothyroidism. In addition to evaluating anthropometric data, medication use, and existence of metabolic syndrome, HRQoL was assessed with the RAND 36-Item Health Survey, and the Ruff Figural Fluency Test was used as a sensitive test for executive functioning. Data on thyrotropin, free thyroxine (fT4), and free T3 (fT3) levels were available in a subset of 4479 participants.The mean age (±standard deviation) was 53 ± 12 years and the body mass index was 27.0 ± 4.5 kg/m2 in the LT4

2016 Thyroid

197. The effect of TSH-suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. (PubMed)

. Bone mineral density (BMD) and TBSs at the lumbar spine were analyzed using dual-energy X-ray absorptiometry (DXA).The association between the parameters of TSH suppressive therapy and bone parameters was investigated.Study subjects showed upper-normal free thyroxine levels and suppressed TSH at DXA evaluation. The mean duration of TSH suppression was 4.4 ± 2.9 years. Serum free T4 and TSH were not independently associated with lumbar spine BMD or TBS levels. Duration of TSH suppression (...) was negatively correlated with lumbar spine TBS levels, but not with BMD. Longer duration of TSH suppression was independently associated with lower lumbar spine TBSs after adjusting for age, body mass index (BMI), and BMD. Lumbar spine TBSs were significantly lower in patients whose duration of TSH suppression was ≥5 years compared with those whose duration was <3 years after adjusting for age, BMI, and BMD.Longer duration of TSH suppression in postmenopausal DTC patients was associated with decreased

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

198. TSH enhancement of FT4 to FT3 conversion is age dependent. (PubMed)

clinics.Free T3, free T4, and TSH levels from 527 564 sera collected from patients aged 1 year or greater were studied. Exclusion criteria were the following: missing data, TSH greater than 7.5mIU/L, and medications that may interfere with thyroid hormone activity. A total of 27 940 samples remaining after exclusion were stratified by age. Samples with available anthropometric data were additionally stratified for body mass index (BMI). Correlations of TSH to FT4, FT3, and FT3/FT4 ratios by age group were (...) TSH enhancement of FT4 to FT3 conversion is age dependent. We previously reported increasing free T3 (FT3) to free T4 (FT4) ratios as thyroid-stimulating hormone (TSH) increases within the normal range in children. It is not known if this phenomenon is age-related among humans, as previously reported in rats. This study examines the relationships between TSH and FT3/FT4 ratios in different ages.Retrospective examination of thyroid tests from patients without thyroid disease from community

Full Text available with Trip Pro

2016 European Journal of Endocrinology

199. Is thyroid status associated with cognitive impairment in elderly patients in China? (PubMed)

) in the elderly Chinese population.In the present study focusing on a population of elderly Chinese individuals ≥ 50 years of age, 77 cognitively normal controls, 64 patients with MCI, and 154 patients diagnosed with AD underwent assessment of thyroid status using thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine (fT4) levels as variables. Cognitive function was evaluated with the aid of comprehensive neuropsychological tests, such as the Mini-Mental State Examination (MMSE (...) ) and Memory and Executive Screening (MES).Overall, 88.1 % of the subjects displayed normal thyroid function, 4.7 % were diagnosed with clinical hypothyroidism, 3.1 % with subclinical hypothyroidism, and 4.1 % with subclinical hyperthyroidism. After adjusting for covariates (age, sex, education years and body mass index), no association was evident between mild cognitive impairment or AD and thyroid dysfunction. However, lower serum TSH was correlated with risk of AD (odds ratio [OR]: 2.78, 95 % confidence

Full Text available with Trip Pro

2016 BMC Endocrine Disorders

200. Thyroid Stimulating Hormone Levels are Associated with Cardiometabolic Risk Factors in Euthyroid Adolescents. (PubMed)

Thyroid Stimulating Hormone Levels are Associated with Cardiometabolic Risk Factors in Euthyroid Adolescents. Increased thyrotropin (TSH) levels and free triiodothyronine to free thyroxine (fT3:fT4) ratios, even within the euthyroid range, have been associated with cardiometabolic risk factors in adults but are less characterized in youth. This study sought to determine relations between TSH, thyroid hormones, and cardiometabolic risk factors in euthyroid adolescents.Data were extracted from (...) the United States National Health and Nutrition Examination Survey, 2007-2010, for univariate and multivariate analyses of TSH, thyroid hormones, body mass index (BMI), blood pressure, lipids, and glucose metabolism. Subjects aged 12-18 years, with normal TSH and antithyroid peroxidase antibody levels, and without a history of thyroid disease, diabetes, or treatment of hypertension/dyslipidemia (n = 1167) were included. TSH and thyroid hormones were assessed for impact on BMI Z-score, systolic blood

Full Text available with Trip Pro

2016 Thyroid

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>